FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDiaSorin S.p.A.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DSRLF
DiaSorin S.p.A. Stock AnalysisComprehensive stock analysis for DiaSorin S.p.A. (DSRLF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDSRLF
DSRLF
DiaSorin S.p.A.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DSRLF
  1. Home
  2. Stocks
  3. DiaSorin S.p.A.

DiaSorin S.p.A.

🇺🇸DSRLF•OTC

DiaSorin S.p.A.

🇺🇸DSRLF•OTC
Market cap
$4.49B
P/E ratio
24.25

Your view on DSRLF

Mkt Cap
$4.49B
P/E
24.25
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About DiaSorin S.p.A.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Carlo Rosa
Headquarters
Via Crescentino snc, Saluggia, VC, IT
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Carlo Rosa
Headquarters
Via Crescentino snc, Saluggia, VC, IT
Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China.

The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample.

It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for DiaSorin S.p.A. from FRC's valuation model, read against the market price. DSRLF last traded at $83.28, 24.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for DiaSorin S.p.A.. Starting points for DiaSorin S.p.A.: P/E 24.2, EPS $3.78, beta 0.62 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for DiaSorin S.p.A.. DiaSorin S.p.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for DiaSorin S.p.A.. Trailing twelve-month EPS for DiaSorin S.p.A. stands at $3.78. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026

Hold

Analyst ratings

4 ratings
  • Strong Buy0
  • Buy1
  • Hold2
  • Sell1
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterSep 2026Next quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateEUR 2.21EUR 2.22EUR 4.31EUR 4.81
Lowest estimateEUR 2.17EUR 2.18EUR 4.24EUR 4.65
Highest estimateEUR 2.24EUR 2.25EUR 4.39EUR 4.96
Number of analysts1122
A year agoEUR 0.09EUR 1.06EUR 2.77—
Growth vs a year ago+2336.5%+109.1%+55.6%—

Revenue estimates

TotalThis quarterSep 2026Next quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateEUR 562.59MEUR 565.40MEUR 1.22BEUR 1.30B
Lowest estimateEUR 555.21MEUR 557.99MEUR 1.19BEUR 1.27B
Highest estimateEUR 568.66MEUR 571.50MEUR 1.25BEUR 1.34B
Number of analysts4388
A year agoEUR 280.00MEUR 575.51MEUR 1.19B—
Growth vs a year ago+100.9%−1.8%+2.1%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for DiaSorin S.p.A.. DiaSorin S.p.A. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DSRLF12 companies
More Medical - Diagnostics & Research companies
TickerTypeCompanySectorExchangeMkt cap
EDTXFSpectral Medical Inc.HealthcareOTC$287.7M
ERFSFEurofins Scientific SEHealthcareOTC$14.4B
FLGTFulgent Genetics, Inc.HealthcareNASDAQ$673.9M
FUNIHypha Labs, Inc.HealthcareOTC$4.0M
GHGuardant Health, Inc.HealthcareNASDAQ$19.7B
GRALGRAIL, Inc.HealthcareNASDAQ$4.5B
GSS.AXGenetic Signatures LimitedHealthcareASX—
HLS.AXHealius LimitedHealthcareASX—
HTGMQHTG Molecular Diagnostics, Inc.HealthcareOTC$221
IBX.AXImagion Biosystems LimitedHealthcareASX—
IBXXFImagion Biosystems LimitedHealthcareOTC$2.2M
ICBUiMD Companies, Inc.HealthcareOTC$7.7M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for DiaSorin S.p.A.. Coverage tracks DiaSorin S.p.A. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of DiaSorin S.p.A.

DSRLF AnalysisFair
Past
4
Growth
1
Health
3
Profit
3
Value
1